Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study

Francesca Palandri, Monia Marchetti, Elena M. Elli, Alessandro Isidori, Ilaria Gianesello, Chiara Sartor, Novella Pugliese, Maria Di Perna, Erika Morsia, Susanna Gallo, Federico Itri, Vittorio Montefusco, Elena Crisà, Annalisa Biagi, Eloise Beggiato, Olga Mulas, Giulia Benevolo, Elisabetta Abruzzese, Marco Santoro, Alessandra Iurlo, Elisabetta Calistri, Marco Rossi, Bruno Martino, Mario Tiribelli, Carmen Fava, Arbana Dizdari, Monica Crugnola, Andrea Duminuco, Amedeo Votto, Selene Guerzoni, Giovanni Caocci, Fabrizio Pane, Francesco Lanza, Filippo Branzanti, Alessandra Dedola, Flavia Salvatore, Florian H. Heidel, Massimo Breccia, Giuseppe A. Palumbo, Andrew T. Kuykendall, Alessandro Lucchesi, Sara Galimberti

Open source

DOI: 10.1002/cncr.70457
Published: 2026-05-12
Container: Cancer
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cncr.70457,
  title = {Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study},
  author = {Francesca Palandri and Monia Marchetti and Elena M. Elli and Alessandro Isidori and Ilaria Gianesello and Chiara Sartor and Novella Pugliese and Maria Di Perna and Erika Morsia and Susanna Gallo and Federico Itri and Vittorio Montefusco and Elena Crisà and Annalisa Biagi and Eloise Beggiato and Olga Mulas and Giulia Benevolo and Elisabetta Abruzzese and Marco Santoro and Alessandra Iurlo and Elisabetta Calistri and Marco Rossi and Bruno Martino and Mario Tiribelli and Carmen Fava and Arbana Dizdari and Monica Crugnola and Andrea Duminuco and Amedeo Votto and Selene Guerzoni and Giovanni Caocci and Fabrizio Pane and Francesco Lanza and Filippo Branzanti and Alessandra Dedola and Flavia Salvatore and Florian H. Heidel and Massimo Breccia and Giuseppe A. Palumbo and Andrew T. Kuykendall and Alessandro Lucchesi and Sara Galimberti},
  year = {2026},
  journal = {Cancer},
  doi = {10.1002/cncr.70457},
  url = {https://doi.org/10.1002/cncr.70457}
}

RIS

TY  - JOUR
TI  - Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study
AU  - Francesca Palandri
AU  - Monia Marchetti
AU  - Elena M. Elli
AU  - Alessandro Isidori
AU  - Ilaria Gianesello
AU  - Chiara Sartor
AU  - Novella Pugliese
AU  - Maria Di Perna
AU  - Erika Morsia
AU  - Susanna Gallo
AU  - Federico Itri
AU  - Vittorio Montefusco
AU  - Elena Crisà
AU  - Annalisa Biagi
AU  - Eloise Beggiato
AU  - Olga Mulas
AU  - Giulia Benevolo
AU  - Elisabetta Abruzzese
AU  - Marco Santoro
AU  - Alessandra Iurlo
AU  - Elisabetta Calistri
AU  - Marco Rossi
AU  - Bruno Martino
AU  - Mario Tiribelli
AU  - Carmen Fava
AU  - Arbana Dizdari
AU  - Monica Crugnola
AU  - Andrea Duminuco
AU  - Amedeo Votto
AU  - Selene Guerzoni
AU  - Giovanni Caocci
AU  - Fabrizio Pane
AU  - Francesco Lanza
AU  - Filippo Branzanti
AU  - Alessandra Dedola
AU  - Flavia Salvatore
AU  - Florian H. Heidel
AU  - Massimo Breccia
AU  - Giuseppe A. Palumbo
AU  - Andrew T. Kuykendall
AU  - Alessandro Lucchesi
AU  - Sara Galimberti
PY  - 2026
JO  - Cancer
DO  - 10.1002/cncr.70457
UR  - https://doi.org/10.1002/cncr.70457
ER  -

APA

Palandri, F., Marchetti, M., Elli, E. M., Isidori, A., Gianesello, I., Sartor, C., Pugliese, N., Perna, M. D., Morsia, E., Gallo, S., Itri, F., Montefusco, V., Crisà, E., Biagi, A., Beggiato, E., Mulas, O., Benevolo, G., Abruzzese, E., Santoro, M., Iurlo, A., Calistri, E., Rossi, M., Martino, B., Tiribelli, M., Fava, C., Dizdari, A., Crugnola, M., Duminuco, A., Votto, A., Guerzoni, S., Caocci, G., Pane, F., Lanza, F., Branzanti, F., Dedola, A., Salvatore, F., Heidel, F. H., Breccia, M., Palumbo, G. A., Kuykendall, A. T., Lucchesi, A., & Galimberti, S. (2026). Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study. Cancer. https://doi.org/10.1002/cncr.70457

Source records

crossref · retrieved 2026-09-26T18:14:41.180Z